#Novartis shares dipped lower this morning after the company revealed its Lp(a)-targeted drug, #pelacarsen, failed to reduce #cardiovascular risks in a major phase 3 trial.

pharmaphorum.com/news/novarti...

Lp(a)HORIZON missed its primary endpoint.

#Pelacarsen substantially lowered Lp(a).

But.....CV death, MI, stroke and urgent revascularization did not fall significantly vs placebo.